

## Why Choose Us?

- Sterile compounding in ISO-certified cleanroom environments
- Independent third-party batch testing for potency, sterility, endotoxins, and purity
- FDA-registered API sourcing with full Certificates of Analysis
- High-quality sterile packaging and temperature-controlled fulfillment
- Reliable turnaround times to support clinic workflows

**Our role is to remove variability in compounding so providers can focus on patient care and clinical decision-making.**

## Important Information

- Sermorelin is a compounded medication and is not FDA-approved
  - Prescribed and dispensed under 503A regulations
    - Intended for patient-specific prescriptions only
      - We do not provide dosing recommendations or clinical protocols. **All medical decisions remain with the licensed provider**

This material is intended for licensed healthcare providers only. Not for patient distribution. No clinical outcomes are implied or guaranteed.

# Sermorelin

## A Provider-Directed Option for Growth Hormone Stimulation

**Sterile compounded formulation**  
Prepared for patient-specific  
use under 503A regulations





## What is Sermorelin?

Sermorelin is a synthetic analog of Growth Hormone–Releasing Hormone (GHRH 1–29), designed to stimulate the body’s natural release of growth hormone via the pituitary gland.

Unlike exogenous growth hormone, Sermorelin works through **physiologic signaling pathways**, allowing providers to evaluate its role within structured, provider-directed care models.

Sermorelin is compounded and prescribed for **patient-specific use only** and is not FDA-approved.

## Historical & Clinical Context

### Clinical Background

Sermorelin originated from early endocrinology research in the late **1970s and 1980s** focused on hypothalamic hormone signaling.



Researchers identified Sermorelin (GHRH 1–29) as the shortest biologically active fragment capable of stimulating endogenous growth hormone release. It was initially studied in pediatric endocrinology to assess pituitary responsiveness.



Over time, provider interest expanded into hormone optimization and wellness-focused care models, where clinicians evaluate growth hormone–stimulating therapies based on clinical judgment.



Interest in growth hormone–stimulating options has increased as providers explore approaches aligned with physiologic signaling rather than hormone replacement.

## How Providers Consider It

### Why Providers Evaluate Sermorelin

Providers may evaluate Sermorelin because it:

- Stimulates endogenous growth hormone release through pituitary signaling
- Aligns with provider-directed hormone and wellness programs
- Integrates into existing care models without requiring in-office procedures
- Supports structured protocols determined entirely by the prescribing provider

Providers assessing Sermorelin often include hormone optimization, longevity-focused, wellness-oriented, or metabolic care practices.

Clinical use, protocols, and patient selection are determined solely by the prescribing provider.